Skip to main content
. 2018 Nov 14;363:k4365. doi: 10.1136/bmj.k4365

Fig 2.

Fig 2

Subgroup analyses of serious adverse events among sodium glucose cotransporter 2 (SGLT2) inhibitor users compared with glucagon-like peptide 1 (GLP1) receptor agonist users. P values for homogeneity (all >0.05) are shown in supplementary materials, table 13. *Number of events not specified for <3 according to regulations on reporting Danish register data.